Acquired resistance to gefitinib is most commonly conferred upon a patient by the EGFR T790M mutation, which has been detected in 50% of NSCLC cases with acquired resistance and in cell line models that have been selected for gefitinib resistance (3). This evidence concerns the gene EGFR and non-small cell lung carcinoma.